Dexcom unveils G8 continuous glucose monitor

Dexcom used its May 14 investor day to introduce G8, its next-generation continuous glucose monitor, and to frame the device as the company’s next hardware step after G7. CEO Jake Leach presented the product during the San Diego company’s webcast for investors, and Dexcom’s posted slide deck identified G8 as “factory calibration and self-adapting.” The presentation did not read like a regulatory filing or product launch notice with pricing and clearance dates. Instead, Dexcom placed G8 inside a broader strategy update that also covered automated insulin delivery, software tools including Smart Basal and Smart Bolus, and wider use of continuous glucose monitoring in type 2 diabetes and metabolic health. ### What, exactly, did Dexcom say about G8? (investors.dexcom.com) Dexcom’s May 2026 investor presentation devoted several slides to what it called the “next step-change” in continuous glucose monitoring. The deck said customer feedback still centers on glucose reliability and described G8 on slide 30 as “factory calibration and self-adapting.” Jake Leach announced G8 during the event, according to MobiHealthNews and Drug Delivery Business, both of which reported on the presentation Thursday. (investors.dexcom.com) Drug Delivery Business said Leach described new technology behind the system, while MobiHealthNews reported that Dexcom showed product images during the event. ### How is G8 different from the current G7? (investors.dexcom.com) Outside reports published on May 14 said Dexcom is positioning G8 as a smaller device with more adaptive sensing. Juicebox Podcast, citing the investor day event, reported the wearable is 50% smaller than G7 and is designed to adapt during wear, though Dexcom’s investor relations summary page itself did not list that size figure in the excerpted slide text. (mobihealthnews.com) Dexcom’s slide excerpts point to the same theme without giving full technical specifications in the webpage text. The investor page says slide 29 is titled “The step-change: A sensor that adapts during use,” and slide 30 is titled “Dexcom G8: Factory Calibration and Self-Adapting.” ### Why does a new CGM generation matter to users and clinicians? Continuous glucose monitors generate large streams of data rather than isolated finger-stick readings. (juiceboxpodcast.com) A review article indexed by the National Library of Medicine said CGM systems provide between 288 readings a day, when measuring every five minutes, and 1,440 readings a day, when measuring every minute. (investors.dexcom.com) That same review said trend arrows show whether glucose is rising, falling or staying stable based on recent rate-of-change. The article said those arrows help users and clinicians decide when to adjust insulin, eat carbohydrates or otherwise respond to changing glucose levels. ### Did Dexcom give a launch timeline? Dexcom’s investor day notice, published May 5, said the May 14 event would cover innovation efforts and long-term financial outlook, but it did not include a commercialization date for G8. (pmc.ncbi.nlm.nih.gov) The investor relations page available after the event lists the G8 slides and says the webcast will be archived for future reference. Outside reports on May 14 and May 15 pointed to a later rollout window. Juicebox Podcast said G8 is expected in late 2027 or early 2028, but Dexcom’s own investor page excerpts visible in search results do not independently confirm that date range. ### Where does G8 fit in Dexcom’s broader plan? Dexcom used the same presentation to argue that continuous glucose monitoring has room to expand beyond its traditional base. (investors.dexcom.com) The company’s slide excerpts refer to “clinical momentum” for broader CGM use, personalization for type 2 non-insulin users, and share gains in primary care and type 2 basal patients. May 14 was also the date Dexcom announced governance changes ahead of investor day, saying the company was positioning itself for future growth under Leach, who became president and chief executive officer earlier this year. (juiceboxpodcast.com) Dexcom said investors can review the archived webcast and May 2026 presentation materials through its investor relations site as the next public record of the G8 rollout takes shape. (investors.dexcom.com 1) (investors.dexcom.com 2)